Ophthotech Corporation (NASDAQ:OPHT) released its quarterly earnings data on Wednesday. The biopharmaceutical company reported ($0.62) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.07) by $0.45, Morningstar.com reports. The business had revenue of $1.66 million for the quarter, compared to analysts’ expectations of $1.38 million. During the same quarter in the prior year, the firm earned ($0.85) earnings per share. Ophthotech Corporation’s quarterly revenue was down 94.1% compared to the same quarter last year.
Ophthotech Corporation (OPHT) traded up 1.48% on Thursday, reaching $2.75. 181,733 shares of the company’s stock were exchanged. The firm has a 50 day moving average of $2.67 and a 200 day moving average of $3.33. Ophthotech Corporation has a 12 month low of $2.24 and a 12 month high of $65.96. The stock’s market capitalization is $98.59 million.
In other news, Chairman David R. Guyer sold 17,678 shares of Ophthotech Corporation stock in a transaction that occurred on Wednesday, July 5th. The shares were sold at an average price of $2.58, for a total value of $45,609.24. Following the transaction, the chairman now owns 37,692 shares of the company’s stock, valued at $97,245.36. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. In the last three months, insiders sold 34,609 shares of company stock worth $89,249. Insiders own 2.00% of the company’s stock.
Several large investors have recently made changes to their positions in the company. Morgan Stanley increased its stake in shares of Ophthotech Corporation by 839.7% in the first quarter. Morgan Stanley now owns 2,229,151 shares of the biopharmaceutical company’s stock valued at $8,159,000 after buying an additional 1,991,921 shares during the last quarter. Renaissance Technologies LLC bought a new stake in shares of Ophthotech Corporation during the first quarter valued at about $6,801,000. Stonepine Capital Management LLC increased its stake in shares of Ophthotech Corporation by 53.4% in the first quarter. Stonepine Capital Management LLC now owns 3,516,489 shares of the biopharmaceutical company’s stock valued at $12,870,000 after buying an additional 1,223,589 shares during the last quarter. Acadian Asset Management LLC bought a new stake in shares of Ophthotech Corporation during the first quarter valued at about $2,157,000. Finally, Quantitative Investment Management LLC increased its stake in shares of Ophthotech Corporation by 452.0% in the first quarter. Quantitative Investment Management LLC now owns 564,100 shares of the biopharmaceutical company’s stock valued at $2,064,000 after buying an additional 461,900 shares during the last quarter. Institutional investors and hedge funds own 73.96% of the company’s stock.
ILLEGAL ACTIVITY WARNING: “Ophthotech Corporation (NASDAQ:OPHT) Announces Quarterly Earnings Results” was originally published by StockNewsTimes and is owned by of StockNewsTimes. If you are accessing this story on another domain, it was stolen and reposted in violation of US and international trademark & copyright laws. The original version of this story can be read at https://stocknewstimes.com/2017/07/27/ophthotech-corporation-nasdaqopht-announces-quarterly-earnings-results.html.
Separately, Zacks Investment Research upgraded shares of Ophthotech Corporation from a “hold” rating to a “buy” rating and set a $3.25 price objective for the company in a research note on Tuesday, May 2nd. Twelve equities research analysts have rated the stock with a hold rating and one has given a buy rating to the company. Ophthotech Corporation presently has a consensus rating of “Hold” and an average target price of $53.53.
About Ophthotech Corporation
Ophthotech Corporation is a biopharmaceutical company. The Company is engaged in the development of therapeutics to treat ophthalmic diseases, with a focus on diseases of the back of the eye. Its primary focus is developing therapeutics for age-related macular degeneration (AMD), which is a disorder of the central portion of the retina, known as the macula, that may result in blindness.
Receive News & Ratings for Ophthotech Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ophthotech Corporation and related companies with MarketBeat.com's FREE daily email newsletter.
